...
首页> 外文期刊>Cell death & disease. >Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-κB signaling
【24h】

Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-κB signaling

机译:巨噬细胞通过NF-κB信号传导激活乳腺癌对PI3K抑制剂GDC-0941的抵抗力

获取原文
           

摘要

The PI3K pathway is one of the most dysregulated signaling pathways in epithelial cancers and has become an attractive therapeutic target under active preclinical and clinical development. However, recent clinical trial studies revealed that blockade of PI3K activity in advanced cancer often leads to the development of resistance and relapse of the diseases. Intense efforts have been made to elucidate resistance mechanisms and identify rational drug combinations with PI3K inhibitors in solid tumors. In the current study, we found that PI3K inhibition by GDC-0941 increased macrophage infiltration and induced the expression of macrophage-associated cytokines and chemokines in the mouse 4T1 breast tumor model. Using the in vitro co-culture system, we showed that the presence of macrophages led to the activation of NF-κB signaling in 4T1 tumor cells, rendering tumor cells resistant to PI3K inhibition by GDC-0941. Furthermore, we found that Aspirin could block the activation of NF-κB signaling induced by PI3K inhibition, and combined use of GDC-0941 and Aspirin resulted in attenuated cell growth and enhanced apoptosis of 4T1 cells in the in vitro co-culture system with the presence of macrophages. Consistently, the combination treatment also effectively reduced tumor burden, macrophage infiltration and pulmonary metastasis in in vivo 4T1 breast tumor model. Together, our results suggested macrophages in microenvironment may contribute to the resistance of breast cancer cells to PI3K inhibition and reveal a new combination paradigm to improve the efficacy of PI3K-targeted therapy.
机译:PI3K途径是上皮癌中最令人讨发的信号通路之一,并且在活性临床前和临床开发中已成为具有吸引力的治疗目标。然而,最近的临床试验研究表明,晚期癌症中的PI3K活性势常导致疾病的抗性和复发的发展。已经阐明了阐明抗性机制并鉴定了实体瘤中PI3K抑制剂的合理药物组合。在目前的研究中,我们发现PI3K通过GDC-0941抑制增加巨噬细胞浸润,并诱导小鼠4T1乳腺肿瘤模型中巨噬细胞相关细胞因子和趋化因子的表达。使用体外共培养系统,我们表明巨噬细胞的存在导致4T1肿瘤细胞中NF-κB信号传导的激活,通过GDC-0941使抗PI3K抑制的肿瘤细胞。此外,我们发现阿司匹林可以阻断通过PI3K抑制诱导的NF-κB信号传导的活化,并将GDC-0941和阿司匹林的组合使用导致减毒的细胞生长和增强4T1细胞在体外共培养系统中的凋亡和增强的细胞凋亡存在巨噬细胞。始终如一地,联合治疗还有效地减少了体内4T1乳腺肿瘤模型中的肿瘤负荷,巨噬细胞浸润和肺转移。我们的结果表明微环境中的巨噬细胞可能导致乳腺癌细胞对PI3K抑制的抵抗力,并揭示了一种新的组合范式,以提高PI3K靶向治疗的功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号